Reteplase

In the US, Reteplase (reteplase systemic) is a member of the drug class thrombolytics and is used to treat Heart Attack.

US matches:

• Reteplase


• Reteplase, recombinant Intravenous


• Reteplase, Recombinant

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

B01AD07

CAS registry number (Chemical Abstracts Service)

0133652-38-7

Chemical Formula

C1736-H2653-N499-O522-S22

Molecular Weight

39573

Therapeutic Category

Anticoagulant agent: Fibrinolytic enzyme

Chemical Name

173-L-Serine-174-L-tyrosine-175-L-glutamine-173-527-plasminogen activator (human tissue-type)

Foreign Names

• Reteplasum (Latin)
• Reteplase (German)
• Reteplase (French)
• Reteplasa (Spanish)

Generic Names

• Reteplase (OS: BAN, USAN)
• BM 06022 (IS: Boehringer Mannheim)
• r-PA (IS)

Brand Names

• Rapilysin
  Actavis, United Arab Emirates; Actavis, Austria; Actavis, Australia; Actavis, Belgium; Actavis, Bahrain; Actavis, Switzerland; Actavis, Germany; Actavis, Denmark; Actavis, Finland; Actavis, France; Actavis, United Kingdom; Actavis, Greece; Actavis, Croatia (Hrvatska); Actavis, Ireland; Actavis, Italy; Actavis, Kuwait; Actavis, Luxembourg; Actavis, Netherlands; Actavis, Oman; Actavis, Portugal; Actavis, Qatar; Actavis, Romania; Actavis, Saudi Arabia; Actavis, Sweden; Actavis, Slovakia; Actavis, Yemen; Actavis Group, Spain; Actavis Group, Iceland; Healthcare Logistics, New Zealand; Roche, Norway



• Retavase
  Biovail, Canada; Centocor, United States

International Drug Name Search

Glossary

BAN	British Approved Name
IS	Inofficial Synonym
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.